In this article, we will be taking a look at the 7 Most Promising Gene Editing Stocks According to Analysts. 

Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, delete, or modify DNA within living cells. Once confined largely to research labs, the field has entered a clinical and commercial phase, led by CRISPR-Cas systems. A major milestone was reached in December 2023, when the U.S. Food and Drug Administration approved Casgevy for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia. This was followed by regulatory clearances across Europe and other regions through 2024 and 2025.

Market growth has accelerated in tandem with these regulatory wins. According to Precedence Research, the global gene-editing market was valued at approximately $9.30 billion in 2024 and is estimated to reach $10.77 billion in 2025. Long-term forecasts point to a market approaching $40 billion by 2034, implying a sustained compound annual growth rate of about 15.7% between 2025 and 2034. The U.S. market mirrors this trajectory, with genome-editing revenues rising from $5.25 billion in 2024 to a projected $24.81 billion by 2034, reflecting a CAGR of 16.8%.

Beyond first-generation therapies, next-wave programs are advancing quickly. Oncology, in vivo liver and cardiovascular applications, and base-editing approaches are moving deeper into clinical development. In early 2024, Beam Therapeutics dosed its first U.S. patient in a base-editing sickle cell trial, while Intellia’s CRISPR programs for transthyretin amyloidosis advanced toward phase 3.

Looking ahead, the sector is expected to sustain mid-teens growth through 2034 as late-stage trials expand, regulatory frameworks mature, and enabling technologies, from advanced delivery systems to AI-driven design, scale across U.S. biotech and academic labs.

Our Methodology

For our methodology, we first analyzed several gene-editing-focused ETFs, including the ARK Genomic Revolution ETF, focusing on companies actively engaged in developing and commercializing gene‑editing technologies. From this analysis, we selected stocks with strong upside potential and ranked them in ascending order based on their PT upside as of December 17.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

Here is our list of the 11 most promising gene editing stocks according to analysts.

7. 10x Genomics, Inc. (NASDAQ:TXG)

Price Target Upside: 6.25%

10x Genomics, Inc. (NASDAQ:TXG) is one of the eight stocks on our list of most promising stocks.

On December 15, 2025, Barclays analyst Luke Sergott raised the price target for TXG from $17 to $22 while maintaining an Overweight rating, reflecting confidence in the company’s positioning in life sciences tools and expectations of stabilizing end‑market demand. Barclays cited improving conditions for research funding and the tools sector as part of its positive outlook.

In contrast, on December 11, 2025, Citigroup downgraded 10x Genomics, Inc. (NASDAQ:TXG) from Buy to Neutral with an $18 price target, highlighting uncertainty about capital expenditures in academic and biopharma research that could weigh on instrument sales recovery.

These differing assessments are grounded in the recent operational context. For the full‑year 2024, 10x Genomics, Inc. (NASDAQ:TXG) reported revenue of approximately $610.8 million, a slight year‑over‑year decline, reflecting soft demand in some core research segments. Analyst caution also stems from guidance for 2025 that implies modest growth, with revenue expected to be roughly flat given continued funding uncertainty in key markets.

10x Genomics, Inc. (NASDAQ:TXG) is a biotechnology company that develops advanced tools for high‑resolution genomic analysis, especially single‑cell and spatial biology technologies. It is not a traditional gene‑editing therapeutic developer (e.g., it does not create CRISPR‑based drugs), but its platforms are widely used to analyze the effects of gene editing in cells and tissues.

6. Twist Biosciences Corporation (NASDAQ:TWST)

Price Target Upside: 9.65%

Twist Biosciences Corporation (NASDAQ:TWST) is one of the most promising stocks on our list.

TheFly reported on December 15 that Barclays raised its price target for TWST from $37 to $39 while maintaining an Overweight rating, reflecting confidence in the company’s margin progress and anticipated performance in the life sciences tools sector.

This follows an Overweight initiation on November 3, 2025, by Stephens with a $41 price target, citing Twist Bioscience (NASDAQ: TWST)’s proprietary silicon‑based DNA synthesis platform as a competitive advantage in synthetic biology and research markets.

Strategic product launches have reinforced investor interest. On December 4, 2025, TWST introduced research‑grade Plasmid DNA Preps designed to support pre‑clinical nucleic acid therapeutics research with animal origin‑free and transfection‑grade options, positioning the company as a more integral supplier for biotech and pharmaceutical discovery workflows.

Twist Bioscience (NASDAQ: TWST) is a biotechnology company that has developed a proprietary silicon‑based DNA synthesis platform to “write” DNA, a core enabling technology for modern genetic research and engineering.